Aclaris Therapeutics, Inc.
ACRS
$1.49
-$0.05-3.25%
| Weiss Ratings | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.11 | |||
| Price History | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.78% | |||
| 30-Day Total Return | -35.50% | |||
| 60-Day Total Return | -41.11% | |||
| 90-Day Total Return | -62.37% | |||
| Year to Date Total Return | -39.92% | |||
| 1-Year Total Return | 19.20% | |||
| 2-Year Total Return | -82.73% | |||
| 3-Year Total Return | -91.28% | |||
| 5-Year Total Return | 35.45% | |||
| 52-Week High % Change | -70.21% | |||
| 52-Week Low % Change | 61.85% | |||
| Price | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $5.17 | |||
| 52-Week Low Price | $0.95 | |||
| 52-Week Low Price (Date) | May 29, 2024 | |||
| 52-Week High Price (Date) | Nov 19, 2024 | |||
| Valuation | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 166.19M | |||
| Enterprise Value | -35.10M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.51 | |||
| Earnings Per Share Growth | 18.54% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 7.84 | |||
| Price/Book (Q) | 1.07 | |||
| Enterprise Value/Revenue (TTM) | -1.88 | |||
| Price | $1.49 | |||
| Enterprise Value/EBITDA (TTM) | 0.67 | |||
| Enterprise Value/EBIT | 0.67 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 95.31M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 484 324 7933 | |||
| Address | 701 Lee Road Wayne, PA 19087 | |||
| Website | www.aclaristx.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -280.57% | |||
| Profit Margin | -705.43% | |||
| Management Effectiveness | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -15.72% | |||
| Return on Equity | -- | |||
| Income Statement | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 18.72M | |||
| Total Revenue (TTM) | 18.72M | |||
| Revenue Per Share | $0.20 | |||
| Gross Profit (TTM) | -47.86M | |||
| EBITDA (TTM) | -52.22M | |||
| EBIT (TTM) | -52.53M | |||
| Net Income (TTM) | -132.07M | |||
| Net Income Avl. to Common (TTM) | -132.07M | |||
| Total Revenue Growth (Q YOY) | -47.58% | |||
| Earnings Growth (Q YOY) | -6,375.65% | |||
| EPS Diluted (TTM) | -1.51 | |||
| EPS Diluted Growth (Q YOY) | -4,216.17% | |||
| Balance Sheet | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 113.59M | |||
| Cash Per Share (Q) | $1.19 | |||
| Total Current Assets (Q) | 125.95M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 155.55M | |||
| Current Ratio (Q) | 3.986 | |||
| Book Value Per Share (Q) | $1.44 | |||
| Total Assets (Q) | 220.33M | |||
| Total Current Liabilities (Q) | 31.60M | |||
| Total Debt (Q) | 2.60M | |||
| Total Liabilities (Q) | 64.77M | |||
| Total Common Equity (Q) | 155.55M | |||
| Cash Flow | ACRS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -69.77M | |||
| Cash from Financing (TTM) | 74.54M | |||
| Net Change in Cash (TTM) | -15.31M | |||
| Levered Free Cash Flow (TTM) | -59.11M | |||
| Cash from Operations (TTM) | -20.08M | |||
